Table 1.

Selected all-grade adverse events associated with the targeted agents sunitinib, sorafenib, bevacizumab/IFN-α, temsirolimus, everolimus, and pazopanib, approved in Europe and/or the United States for the treatment of metastatic RCC

Adverse event (%)SunitinibSorafenibBevacizumab plus IFN-αTemsirolimusEverolimusPazopanib
Anorexia341636321622
Asthenia2032511814
Diarrhea614320271752
Dyspnea101413288
Fatigue5437332019
Hand–foot syndrome2930
Hyperglycemia265041
Proteinuria18
Hypertension20172640
Anemia798104591
Lymphopenia684231
Neutropenia77771134
Thrombocytopenia686142032
Leucopenia7862632
Discontinuations due to AEs (%)191028710NR

NOTE: Data from refs. 6, 64–68.

Abbreviations: AE, adverse event; NR, not reported.